No Data
Beijing Tiantan Biological Products Corporation (600161): Profitability enhanced, license expansion helps to open up new sources for plasma collection.
The company released its 2024 third-quarter report: In the first three quarters of 2024, it achieved revenue of 4.073 billion yuan, net income attributable to the mother 1.052 billion yuan, non-net profit attributable to the mother 1.044 billion yuan, year-on-year growth of 1.28% respectively.
Beijing Tiantan Biological Products Corporation (600161.SH): The "Human Prothrombin Complex" developed has completed clinical ethical review, pre-clinical preparation for inclusion and other work, and officially started phase III clinical trials recently.
Gelonghui October 31st news | beijing tiantan biological products corporation (600161.SH) announced that the "Human Prothrombin Complex" developed by its subsidiary guizhou biological pharmaceutical co., ltd. of China National Pharmaceutical Group has completed the clinical ethical review, pre-clinical recruitment preparation, and officially launched phase III clinical trials in recent days.
Earnings Beat: Beijing Tiantan Biological Products Co., Ltd. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models
Beijing Tiantan Biological Products Corporation (600161): The company's profit in Q3 2024 remained stable, with another successful external acquisition.
Event: On October 25, 2024, the company released the third quarter report of 2024: the company's revenue for the first three quarters of 2024 was 4.073 billion yuan (YoY +1.28%), and the net income attributable to shareholders was 10.
Beijing Tiantan Biological Products' Q3 Profit Inches Up 2%
Tiantan Biotech Report for the Third Quarter of 2024
No Data
No Data